AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01436357 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-NSmut
Description: Stages I and II: 1 dose of MVA-NSmut at the dosage 1.8 x10\^8 plaque forming units (pfu) intramuscularly on day 56.
Study NCT01436357 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Stages I and II: Two doses of placebo intramuscularly, 1 at day 0 and 1 at day 56.
Study NCT03217318 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ureteral stenting with standard or modified ureteral stent
Description: Ureteral stenting because of kidney and or ureteral stones at the iliacal vessel crossing of the ureter or proximally
Study NCT04459923 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound-guided erector spinae plane block catheter
Description: for postoperative pain management ultrasound-guided erector spine plane block catheter placement
Study NCT04459923 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: thoracic epidural catheter
Description: for postoperative pain management thoracic epidural catheter placement
Study NCT04520867 — intervention group
Intervention type: OTHER
Intervention: STRENGTH
Description: Patients with esophageal (EC) and gastroesophageal junction (GEJC) cancers who are seen in the Esophageal and Gastric Multidisciplinary Clinic (EGMDC) for treatment planning and are recommended to receive neoadjuvant therapy and plan to receive treatment at UCCC Metro will be offered enrollment into the study. Patients will complete the patient reported assessments focused on QOL and physical activity on provided tablet computers during UCCC visits at specified time points. If unable to complete assessments in person they will be e-mailed to the patient via REDCap to complete. Additional data regarding dosing of chemotherapy, radiation, nutrition and surgical outcomes will be collected.
Study NCT00620737 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Human Fibroblasts (Isolagen TherapyTM)
Description: 1. Collection of skin biopsy.~2. Administration of 2 study injections~3. Performance of various study assessments during clinic visits
Study NCT00620737 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1. Collection of skin biopsy.~2. Administration of 2 study injections~3. Performance of various study assessments during clinic visits
Study NCT00108277 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breathing Training-Raise CO2
Description: while breathing 9 breaths per minute, patients are instructed to raise CO2
Study NCT00108277 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Breathing Training- Lower CO2
Description: while breathing 9 breaths per minute, patients are instructed to lower CO2
Study NCT03217240 — intervention group
Intervention type: OTHER
Intervention: Blood Sampling for all participants
Description: Serum samples will be obtained before CMR. The sample will be stored at -80 degree until assay. Investigators will perform various tests related to participants heart function
Study NCT01310270 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pro-Omega
Description: Pro-Omega, 4.4gm/day x 1 month
Study NCT01310270 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Omega 3 Fatty Acid
Description: 4.4 gm/day for 1 month
Study NCT01310270 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega 3 Fatty Acid
Description: 4.4 gm/day for 1 month
Study NCT04181723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trofinetide
Description: Trofinetide solution administered based on the subject's weight at Baseline, twice daily for 12 weeks
Study NCT04181723 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Trofinetide placebo solution administered based on the subject's weight at Baseline, twice daily for 12 weeks
Study NCT04098289 — intervention group
Intervention type: PROCEDURE
Intervention: Hysteroscopic septum resection
Description: Hysteroscopic septum resection, using a 26 French continuous-flow resectoscope with monopolar energy and electrolyte-free distension medium.
Study NCT04098289 — intervention group
Intervention type: PROCEDURE
Intervention: In vitro fertilization
Description: Fertilization of oocytes with the spermatozoa of the partner, after induction of ovulation and capacitation of the sperm, using fertilization in vitro and embryo transfer (FIVET) or intracytoplasmic sperm injection (ICSI).
Study NCT00718835 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: incentive-based contingency management
Description: Direct comparison of Contingent versus Noncontingent incentives in promoting abstinence from smoking among opioid-treatment patients. The biochemical measures of breath carbon monoxide levels and urinary cotinine are used to confirm smoking status. Participants receive voucher-based incentives either contingent upon demonstrating abstinence from recent smoking (Contingent condition) or independent of smoking status (Noncontingent control condition).
Study NCT00718835 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: incentive-based contingency management
Description: Direct comparison of Contingent versus Noncontingent incentives in promoting abstinence from smoking among opioid-treatment patients. The biochemical measures of breath carbon monoxide levels and urinary cotinine are used to confirm smoking status. Participants receive voucher-based incentives either contingent upon demonstrating abstinence from recent smoking (Contingent condition) or independent of smoking status (Noncontingent control condition).
Study NCT01502098 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Postoperative early passive motion
Description: Shoulder exercises starting on the first postoperative day
Study NCT01502098 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Sling
Description: Sling for 4 weeks
Study NCT00653744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Study NCT04184505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: 75mg/mq/day subcutaneously for 7 days every 28 days
Study NCT04184505 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Chemotherapy
Description: 1. cycle (induction): i.v. 3+7 (Citarabine 200 mg/m2 iv continuous infusion (24 h) for 7 days, Daunorubicine 60 mg/mq iv day 1-3)~2. cycle (consolidation): i.v. 3+7 (Citarabine 200 mg/m2 iv continuous infusion (24 h) for 7 days, Daunorubicine 45 mg/mq iv day 1-3)
Study NCT04184505 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic stem cell transplantation
Description: Allogeneic stem cell transplantation
Study NCT04184505 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Allogeneic stem cell transplantation
Description: Allogeneic stem cell transplantation
Study NCT00759187 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluoride
Description: Brush twice daily
Study NCT00759187 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triclosan/Fluoride
Description: Half mouth toothbrushing twice daily for 4 days
Study NCT04682418 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: xvision Spine sytem
Description: pedicle screw placement will be performed using the XVS navigation system
Study NCT03331575 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Arm1 (Hypofractionated radiotherapy)
Description: hypofractionated RT（PTV-G60.5Gy/22Fx, 2.75Gy/Fx; PTV-C 49.5Gy/22Fx, 2.25Gy/Fx）, with concurrent chemotherapy : Cisplatin(20 mg/m2 d1) Docetaxel (20 mg/m2 d1),weekly, 6 cycles )
Study NCT03331575 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Arm1 (Hypofractionated radiotherapy)
Description: hypofractionated RT（PTV-G60.5Gy/22Fx, 2.75Gy/Fx; PTV-C 49.5Gy/22Fx, 2.25Gy/Fx）, with concurrent chemotherapy : Cisplatin(20 mg/m2 d1) Docetaxel (20 mg/m2 d1),weekly, 6 cycles )
Study NCT00759187 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine Gluconate
Description: Mouth rinsing twice a day for 4 days
Study NCT04305587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07081532
Description: Investigational Drug once daily for up to 42 days; multiple ascending dose design.
Study NCT04305587 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PF-07081532
Description: Investigational Drug once daily for up to 42 days; multiple ascending dose design.
Study NCT04305587 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo once daily for up to 42 days.
Study NCT04305587 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo once daily for up to 42 days.
Study NCT04305587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Part B may include a drug-drug interaction study using open-label clopidogrel. Clopidrogrel may be given as two single doses of 75 mg administered on day -2 and day 41.
Study NCT04305587 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Clopidogrel
Description: Part B may include a drug-drug interaction study using open-label clopidogrel. Clopidrogrel may be given as two single doses of 75 mg administered on day -2 and day 41.
Study NCT01723618 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRD007
Study NCT03812744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Whole coffee cherry extract (WCCE)
Description: 100mg WCCE
Study NCT03812744 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Capsule [CEBOCAP]
Description: Silica Oxide
Study NCT00927797 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, Pentostatin, Rituximab
Study NCT02581722 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PrePex Device
Description: The PrePex device is designed to enable conducting male circumcision procedure that is bloodless with no anesthesia and no sutures. For contraindicated subjects, a preparation procedure will take place.
Study NCT00650208 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamotrigine Tablets 25 mg
Description: 2x25mg, single dose fasting
Study NCT00653744 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Study NCT04036344 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Mentorship Program
Description: Mentee participants are paired with a previous MMS patient (Mentor) who is greater than 1 year status post MMS treatment for a facial skin cancer. Mentors and mentees maintain regular contact by telephone, video chat, or in-person meetings throughout the mentee's facial skin cancer treatment with MMS.
Study NCT00650208 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamictal® Tablets 25 mg
Description: 2x25mg, single dose fasting
Study NCT04249674 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Dextrometorphan
Description: Administration of 4 ml=10 mg of Dextrometorphan (Bexine sirup)
Study NCT04249674 — intervention group
Intervention type: GENETIC
Intervention: Genotyping by single nulcetoide polymorphism.
Description: Single nucleotide polymorphism determination
Study NCT03104959 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: N-acetyl cysteine
Study NCT03206463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4 mg Delta-9-THC
Description: Subject will have 1/3 chance of receiving 4 mg THC administered through a vaporizer, over approximately 20 minutes, followed by approximately 45 minutes of neuropsychological and physiological testing.
Study NCT03104959 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT01507623 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Capnography (Phillips MP20 monitor)
Description: In the intervention group the NAPS nurse observed possible hypoxia and changes in capnography curves/values during the procedure and was instructed to decrease propofol and take actions against insufficient ventilation\* if etCO2 ≥ 7kPa or ≤ 2 kPa for ≥ 1 minute, if respiratory frequency ≤ 8 or a loss of curve shape was registered.~\*Suction, increase oxygen supply, tongue holder or nasal airway, bag-mask ventilation,paged anaesthesia Discontinued procedures
Study NCT03512275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bermekimab Monoclonal Antibody 400 mg
Description: subcutaneous injection
Study NCT02280525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: 2.5 mg by mouth daily on Day -2 to Day +14.
Study NCT02280525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m2 by vein on Day -5 for participants with B-cell cancer.
Study NCT02280525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Lymphodepleting Chemotherapy Option #1: Fludarabine 25 mg/m2 by vein on Days -5 to -3.~Lymphodepleting Chemotherapy Option #2: Fludarabine 25 mg/m2 by vein over 1 hour on Day -6 to -2.~Lymphodepleting Chemotherapy Option #3: Fludarabine 30 mg/m2 by vein over 1 hour on Days -6 to -2
Study NCT02280525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Lymphodepleting Chemotherapy Option #1: Cyclophosphamide 200 mg/m2 by vein on Days -5 to -3.~Lymphodepleting Chemotherapy Option #2: Cyclophosphamide 60 mg/kg by vein over 3 hours on Days -5 and -4.
Study NCT03206463 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subject will have 1/3 chance of receiving the inhaled placebo condition administered through a vaporizer, over approximately 20 minutes, followed by approximately 45 minutes of neuropsychological and physiological testing. The placebo condition will include no active cannabinoids.
Study NCT01738321 — intervention group
Intervention type: OTHER
Intervention: Cuff pressure
Description: Measuring endotracheal tube (ETT) cuff pressure
Study NCT02280525 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: NK Cells
Description: Participant assigned to a dose level of NK cells based on when joined study. Starting dose level of NK cells 1 x 10\^7 NK cells/kg given by vein on Day 0.~NK Cell Infusion Expansion Phase: Maximum tolerated dose of NK cells from Induction Phase.
Study NCT03206463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2 mg Delta-9-THC
Description: Subject will have 1/3 chance of receiving 2 mg THC administered through a vaporizer, over approximately 20 minutes, followed by approximately 45 minutes of neuropsychological and physiological testing.
Study NCT01381666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INS316 solution for inhalation
Description: inhalation via nebulizer given for 2 doses for 60 minutes each
Study NCT01381666 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: hypertonic saline 3% sodium chloride solution
Description: inhalation via nebulizer given for 2 doses for 60 minutes each
Study NCT02280525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Cytarabine 2 mg/m2 by vein on Days -6 to -2.
Study NCT04370405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YY-20394
Description: YY-20394 tablets will be given daily for 28 days in 28-day cycles until there appears evidence of progressive disease, intolerable toxicity, or the subject discontinues from the study treatment for other reasons.
Study NCT03729089 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified Biophysical Profile scan
Description: Modified biophysical profile scan to be done in third trimester for eligible pregnant mothers
Study NCT01161927 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nizatidine
Description: Nizatidine Capsules 300 mg of Dr.Reddy's Laboratories Limited
Study NCT01161927 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Axid
Description: Axid 300 mg Capsules of Reliant Pharmaceuticals, US
Study NCT04125849 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoraco-laparoscopic esophagectomy
Description: Thoraco-laparoscopic esophagectomy surgery
Study NCT04125849 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mediastinoscopy-assisted transhiatal esophagectomy
Description: Mediastinoscopy-assisted transhiatal esophagectomy surgery
Study NCT03547076 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Focused ultrasound diagnostics
Description: Patients first be examined by nurses using a pocket-sized imaging device. Secondly, by a General Practitioner using the pocket-sized imaging device. Thirdly, reference echocardiography will be performed by cardiologist using a high-end echocardiographic scanner. Only tools (ultrasound equipment and dedicated software) approved for clinical practice will be used.~The focused ultrasound examination includes three standard apical views (4-chamber, 2-chamber and long axis) with and without color Doppler, in addition to recordings from both pleural cavities and the inferior vena cava. The reference imaging includes the same recordings, but in addition all other chambers and valves are assessed (grey scale, color Doppler, pulsed wave and continuous wave Doppler and tissue Doppler).
Study NCT00509366 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin & Gemcitabine
Description: Squamous Cell NSCLC:~Gemcitabine 1250 mg/m2 IV over 30 minutes day 1 and 8, followed by Cisplatin 75 mg/m2 IV over 60 minutes day 1; repeat every 21 days for up to 6 cycles
Study NCT00509366 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin & Pemetrexed
Description: Non-Squamous Cell NSCLC:~Pemetrexed 500 mg/m2 IV over approximately 10 minutes day 1, followed by Cisplatin 75 mg/m2 IV over 60 minutes day 1; repeat every 21 days for up to 6 cycles
Study NCT00509366 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel & Gemcitabine
Description: Squamous Cell NSCLC:~Docetaxel 75 mg/m2 IV over 60 minutes day 1, followed by Gemcitabine 1250 mg/m2 IV over 30-60 minutes day 1 and alone day 8; repeat every 21 days for up to 6 cycles
Study NCT01310348 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: whole-body vibration (WBV)
Description: The whole-body vibration (WBV) training group will be trained on a WBV platform (Power Plate) 5 times a week for 4 weeks period. Training volume and training intensity will be low at the beginning but progressed slowly according to the overload principle. The training volume will be increased systematically over the 4-week training period. The training intensity will be increased by increasing the amplitude (2-4 mm) and the frequency (40 Hz) of the vibration.
Study NCT01310348 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: WBV (Sham stimulation)
Description: Sham stimulus will be performed by WBV platform 5 times a week for a 4 weeks period.
Study NCT00439413 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Selegiline Transdermal Patch
Description: Selegiline cm(2) via transdermal system
Study NCT00439413 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo via transdermal system
Study NCT00439413 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Smoking Cessation Counseling
Description: Subjects were provided with on-site, individual smoking cessation counseling sessions 1x per week for 9 weeks
Study NCT00439413 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Smoking Cessation Counseling
Description: Subjects were provided with on-site, individual smoking cessation counseling sessions 1x per week for 9 weeks
Study NCT03614273 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hypertonic saline
Description: The nebulizations were administered via an oxygen run jet nebulizer, with a flow of 6-7 litres/min.
Study NCT03614273 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adrenaline
Description: The nebulizations were administered via an oxygen run jet nebulizer, with a flow of 6-7 litres/min.
Study NCT04930406 — intervention group
Intervention type: OTHER
Intervention: Physical therapy
Description: Had to receive 10 or more visits of physical therapy during the cancer treatment period to qualify for intervention group.
Study NCT01631851 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT) for Irritability
Description: CBT is an individually administered behavioral interventions aimed at reducing irritability and disruptive behavior. There are 10 to 12 weekly sessions that are conducted with the child and the parent. During these sessions children are taught to recognize antecedents and consequences of problem behavior and to use emotion regulation and problem-solving skills to reduce irritability, aggression and noncompliance.
Study NCT00439270 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dasatinib
Description: Tablets, Oral, 50, 70, 100, or 120 mg once daily; treatment may continue until disease progression
Study NCT00439270 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Infusion, 60 or 75 mg/m\^2, administered every 3 weeks.
Study NCT00509366 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed & Gemcitabine
Description: Non-Squamous Cell NSCLC:~Pemetrexed 500 mg/m2 IV over approximately 10 minutes day 1, followed by Gemcitabine 1250 mg/m2 IV over 30-60 minutes day 1 and alone day 8; repeat every 21 days for up to 6 cycles
Study NCT01250886 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactated Ringer's solution
Description: Lactated Ringer's solution is administered. The volume of fluid administration is calculated by means of Holliday and Segar formula.